Soluble urokinase plasminogen activator receptor (suPAR) is a circulating biomarker of inflammation. A recent study identifies immature myeloid cells in the bone marrow as a major cellular source of suPAR that contributes to kidney disease.
This is a preview of subscription content, log in via an institution to check access.
References
Wei, C. et al. Nat. Med. 14, 55–63 (2008).
Wei, C. et al. Nat. Med. 17, 952–960 (2011).
Spinale, J.M. et al. Kidney Int. 87, 564–574 (2015).
Eugen-Olsen, J. et al. J. Intern. Med. 268, 296–308 (2010).
Hayek, S.S. et al. N. Engl. J. Med. 373, 1916–1925 (2015).
Hahm, E. Nat. Med. 23, 100–106 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Shankland, S., Jefferson, J. A bone marrow factor contributes to kidney disease. Nat Med 23, 13–14 (2017). https://doi.org/10.1038/nm.4263
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4263
- Springer Nature America, Inc.
This article is cited by
-
suPAR as a marker of infection in acute kidney injury – a prospective observational study
BMC Nephrology (2018)
-
The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease
Nature Reviews Nephrology (2018)